Author of

• 16751

  +

  P1.05 - Poster Session with Presenters Present (ID 457)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Early Stage NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/05/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 16800

    +

    P1.05-049 - Neoadjuvant Erlotinib Treatment in Patients with Resectable Non-Small Cell Lung Carcinoma (ID 3788)

    14:30 - 15:45  |  Author(s): M.H. Van Gool
    • Abstract

    Background:
    The value of neo-adjuvant therapy in patients with resectable non-small cell lung carcinoma (NSCLC) is limited. Recent advances in targeted therapy have provided novel treatment options for NSCLC with promising results. The Epidermal Growth Factor Receptor (EGFR) is over expressed or may harbour activating mutations in adenocarcinoma in particular. Inhibition of EGFR with tyrosine-kinase inhibitor (TKI) therapy has a favourable outcome in advanced stage patients with activating mutations. The purpose of this study was to prospectively evaluate 18F-FDG-PET metabolic response to neoadjuvant erlotinib, in patients with resectable NSCLC.
    
    Methods:
    This study was designed as a multicentre open-label phase II trial, performed in the Netherlands. Patients received preoperative erlotinib 150 mg once daily for 3 weeks. Metabolic response evaluation was performed using FDG-PET/CT scan. Tumour FDG uptake and changes were measured by standardized uptake values (SUV). Metabolic response was classified using EORTC criteria. Metabolic response was compared to the histopathological response and survival.
    
    Results:
    From December 2006 until November 2010, 60 patients were enrolled in this study. In 43 patients (18 male, 25 female), FDG-PET/CT scans and histopathologic response monitoring were available. 14 patients (33%) showed a metabolic response. Histopathologic examination showed a response in 13 patients (30%). In predicting histopathologic response FDG-uptake showed an area under the curve of 72%. Metabolic responders show an improved overall and progression free survival in comparison to patients without metabolic response.Figure 1
    
    
    
    Conclusion:
    FDG-PET/CT may be used as a predictive tool to identify patients with advantage of neoadjuvant EGFR-TKI treatment in resectable NSCLC.